Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Lorlatinib in Combination with Ramucirumab for Treatment in Patients with Advanced ALK-rearranged Advanced Non-Small Cell Lung Cancer

Trial Status: active

This phase I/II trial studies the side effects and best dose of lorlatinib when given together with ramucirumab and to see how well it works in treating patients with non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and cancer has a change (fusion) involving the ALK gene (called ALK-rearranged). A fusion gene is made in the body when parts of two different genes join together. Lorlatinib is routinely used to treat ALK-rearranged NSCLC and works to prevent cancer spread by interfering with the growth of cancer cells, which are eventually destroyed by the body. Ramucirumab is a type of drug called a monoclonal antibody. Monoclonal antibodies are similar to the antibodies your body makes to fight infections caused by bacteria or viruses. Ramucirumab binds to a molecule called VEGF Receptor 2 (VGFR-2) that promotes the growth of cancer cells. Binding to this receptor may slow or stop the growth and spread of cancer. Giving lorlatinib in combination with ramucirumab may work better in treating patients with advanced ALK-rearranged NSCLC.